2-丙烯酸异辛酯与2-丙烯酰胺的聚合物 | 50922-82-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-丙烯酸异辛酯与2-丙烯酰胺的聚合物
• 英文名称: Isooctylacrylate Acrylamide
• 英文别名: 6-methylheptyl prop-2-enoate;prop-2-enamide
• CAS: 50922-82-2
• 化学式: C14H25NO3
• 分子量: 255.35
• InChiKey: XVKLGCDWSRXKNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.59
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  69.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  異辛基丙烯酸 、 丙烯酰胺 、 过氧化苯甲酰 在 氮 、 乙酸乙酯 、 过氧化苯甲酰 、 solids 、 甲醇乙酸乙酯 作用下， 以 乙酸乙酯 、 甲醇 为溶剂， 反应 14.5h， 生成 2-丙烯酸异辛酯与2-丙烯酰胺的聚合物
  参考文献：
  名称：

  METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY

  摘要：

  制药配方和方法，用于局部和/或经皮递送咪喹莫德（imiquimod），包括乳膏、软膏和压敏粘合剂组合物，用于治疗皮肤疾病，即病毒感染，如I型或II型单纯疱疹感染和生殖器疣，光化性角化症和表浅性基底细胞癌，并诱导干扰素生物合成，比目前由美国食品和药物管理局（“FDA”）批准的咪喹莫德治疗时间更短。

  公开号：

  US20090018155A1

文献信息

• Transdermal device for the delivery of alfuzosin
  申请人：Minnesota Mining and Manufacturing Company

  公开号：US05614210A1

  公开（公告）日：1997-03-25

  A transdermal drug delivery device involving an acrylate or methacrylate based adhesive copolymer, a skin penetration enhancer, and a therapeutically effective amount of alfuzosin.

  一种经皮递药装置，包括丙烯酸酯或甲基丙烯酸酯基粘合共聚物、皮肤穿透增强剂和治疗有效量的阿尔福克辛。
• Transdermal estradiol delivery system
  申请人：Riker Laboratories, Inc.

  公开号：US05223261A1

  公开（公告）日：1993-06-29

  A pressure-sensitive adhesive sheet material for delivering estradiol to skin, the sheet material comprising a backing with a layer of a pressure-sensitive adhesive adjacent thereto, said pressure-sensitive adhesive layer comprising a pressure-sensitive adhesive polymer, two or more skin penetration-enhancing ingredients and estradiol. The sheet material is useful for systemic treatment of conditions associated with estradiol deficiency. Methods of using such adhesive sheet material are also described.

  一种压敏粘合剂片材，用于将雌二醇输送至皮肤，该片材包括一个支撑层和与其相邻的一个压敏粘合剂层，所述压敏粘合剂层包括一个压敏粘合剂聚合物、两种或两种以上的皮肤穿透增强成分和雌二醇。该片材可用于治疗与雌二醇缺乏相关的全身性疾病。还描述了使用这种粘合剂片材的方法。
• Topical formulations and transdermal delivery systems containing
  申请人：Riker Laboratories, Inc.

  公开号：US05238944A1

  公开（公告）日：1993-08-24

  Pharmaceutical formulations and adhesive-coated sheet materials for the topical and/or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, including creams, ointments and pressure-sensitive adhesive compositions. Pharmacological methods of using the formulations and the adhesive-coated sheet materials of the invention in the treatment of viral infections.

  制药配方和粘合涂层的片材，用于局部和/或经皮递送1-异丁基-1H-咪唑[4,5-c]-喹啉-4-胺，包括乳膏、软膏和压敏粘合剂组合物。使用该发明的配方和粘合涂层片材的药理学方法，用于治疗病毒感染。
• METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS
  申请人：Slade Herbert B.

  公开号：US20080280943A1

  公开（公告）日：2008-11-13

  Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure-sensitive adhesive compositions to treat dermatological disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type II Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.

  本发明涉及药物包装和方法，用于增强使用咪喹莫德治疗患有皮肤疾病的儿童的安全性。特别地，通过向儿童、儿童监护人（包括父母和医护人员）提供信息，即在使用咪喹莫德治疗2至12岁儿童时可能观察到咪喹莫德的系统吸收和其他影响，增强了咪喹莫德使用的安全性。系统吸收的示例包括血清咪喹莫德浓度低于约2ng/mL、中位白细胞计数降低约1.4*109/L或中位绝对中性粒细胞计数降低约1.42*109/L。本发明还涉及用于治疗儿童皮肤病的咪喹莫德的局部和/或经皮递送，包括乳膏、软膏、凝胶、洗剂、膏药和压敏粘合剂组合物，用于治疗软疣、病毒感染（如I型或II型单纯疱疹感染和尖锐湿疣）、光化性角化症和浅表性基底细胞癌，并诱导干扰素生物合成。
• LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS
  申请人：Nordsiek Michael T.

  公开号：US20110207766A1

  公开（公告）日：2011-08-25

  Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

  本文公开了用于治疗生殖器/会阴疣的局部或经皮递送1-异丁基-1H-咪唑[4,5-c]-喹啉-4-胺或1-(2-甲基丙基)-1H-咪唑[4,5 c]喹啉-4-胺（即Imiquimod）的制剂和方法，其治疗时间比商业可获得的Aldara® 5% Imiquimod Cream目前所规定的时间更短，已获得美国食品药品监督管理局（FDA）批准。更具体地，本文还公开了较低剂量的Imiquimod制剂，以递送有效剂量的Imiquimod治疗生殖器/会阴疣，并具有可接受的安全性和更短、更方便的用药方案，比美国FDA批准的Aldara® 5% Imiquimod Cream治疗生殖器/会阴疣的用药方案更短。